AROMATASE INHIBITORS - CURRENT STATUS

被引:31
作者
IBRAHIM, NK [1 ]
BUZDAR, AU [1 ]
机构
[1] UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BREAST & GYNECOL MED ONCOL,HOUSTON,TX 77030
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1995年 / 18卷 / 05期
关键词
ESTROGEN; AROMATASE; BREAST CANCER; INHIBITORS;
D O I
10.1097/00000421-199510000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review. source of estrogen in the human body and means of its ablation are discussed with emphasis on aromatase inhibition. Aminoglutethimide was highlighted as the prototype for inhibition of aromatase. All other agents that have aromatase inhibitory effect, as well as, antitumor effect were discussed in reference to their structure, chemistry, pharmacology, and pharmacokinetics in animals and humans. Their respective antitumor effect in experimental studies and humans, including dose-schedules responses and side effects, are also reviewed. New aromatase inhibitors have significant antitumor activity in breast cancer and may have better therapeutic index than currently available drugs.
引用
收藏
页码:407 / 417
页数:11
相关论文
共 142 条
[1]   DIETARY PHYTOESTROGENS AND CANCER - INVITRO AND INVIVO STUDIES [J].
ADLERCREUTZ, H ;
MOUSAVI, Y ;
CLARK, J ;
HOCKERSTEDT, K ;
HAMALAINEN, E ;
WAHALA, K ;
MAKELA, T ;
HASE, T .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 41 (3-8) :331-337
[2]   EFFICACY AND TOLERABILITY OF 4-HYDROXYANDROSTENEDIONE (4-OHA) AS 1ST-LINE TREATMENT IN POSTMENOPAUSAL PATIENTS WITH BREAST-CANCER AFTER ADJUVANT THERAPY [J].
BAJETTA, E ;
ZILEMBO, N ;
BUZZONI, R ;
NOBERASCO, C ;
CELIO, L ;
BICHISAO, E .
CANCER TREATMENT REVIEWS, 1993, 19 :31-36
[3]  
Banting L, 1989, Prog Med Chem, V26, P253, DOI 10.1016/S0079-6468(08)70242-X
[4]   INHIBITION OF PERIPHERAL AROMATIZATION OF ANDROSTENEDIONE TO ESTRONE IN POST-MENOPAUSAL WOMEN WITH BREAST-CANCER USING DELTA-1 TESTOLOLACTONE [J].
BARONE, RM ;
SHAMONKI, IM ;
SIITERI, PK ;
JUDD, HL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 49 (05) :672-676
[5]   HORMONAL CHANGES IN POSTMENOPAUSAL WOMEN WITH BREAST-CANCER TREATED WITH TRILOSTANE AND DEXAMETHASONE [J].
BEARDWELL, CG ;
HINDLEY, AC ;
WILKINSON, PM ;
STJOHN, J ;
BULOCK, D .
CLINICAL ENDOCRINOLOGY, 1985, 23 (04) :413-421
[6]  
BENJAMIN PH, 1991, CANCER CHEMOTHER PHA, V27, P367
[7]   CGS-16949A, A NEW AROMATASE INHIBITOR IN THE TREATMENT OF BREAST-CANCER - A PHASE-I STUDY [J].
BERETTA, KR ;
HOEFFKEN, K ;
KVINNSLAND, S ;
TRUNET, P ;
CHAUDRI, HA ;
BHATNAGAR, AS ;
GOLDHIRSCH, A ;
CAVALLI, F .
ANNALS OF ONCOLOGY, 1990, 1 (06) :421-426
[8]   AROMATIZATION OF ANDROSTENEDIONE BY HUMAN-BREAST CANCER-TISSUE - CORRELATION WITH HORMONE RECEPTOR ACTIVITY AND POSSIBLE BIOLOGIC SIGNIFICANCE [J].
BEZWODA, WR ;
MANSOOR, N ;
DANSEY, R ;
ESSER, JD .
ONCOLOGY, 1987, 44 (01) :30-33
[9]  
BHANTNAGAR AS, 1990, J STEROID BIOCH MOL, V37, P1021
[10]   NOVEL AROMATASE INHIBITORS [J].
BHATNAGAR, AS ;
HAUSLER, A ;
SCHIEWECK, K ;
BROWNE, LJ ;
BOWMAN, R ;
STEELE, RE .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1990, 37 (03) :363-367